PKN activation via transforming growth factor-β1 (TGF-β1) receptor signaling delays G2/M phase transition in vascular smooth muscle cells

被引:19
作者
Su, Chang
Deaton, Rebecca A.
Iglewsky, Myriam A.
Valencia, Thomas G.
Grant, Stephen R.
机构
[1] Univ N Texas, Hlth Sci Ctr, Dept Integrat Physiol, Cardiovasc Res Inst, Ft Worth, TX 76107 USA
[2] Univ Virginia, Charlottesville, VA USA
关键词
PKN; TGF-beta; 1; smooth muscle; G(2)/M phase; cell cycle;
D O I
10.4161/cc.6.6.3985
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The transition of vascular smooth muscle cells (VSMCs) from G(2) phase into the M (mitosis) phase of the cell cycle is a tightly controlled process. As an arterial SMC prepares for a G(2)/M transition, the cell has primed the Cdc2/cyclinB1 complex for activation by the phosphorylation of threonine-161 residue on Cdc2. This phosphorylation is necessary but not sufficient for the VSMC to enter into the M phase. In order to enter into mitosis, a phosphatase, Cdc25C, must first dephosphorylate two other critical residues: tyrosine-15 and threonine-14. If Cdc25C phosphatase activity is blocked, VSMC entry into mitosis is delayed. However, how the activity of Cdc25C is regulated has not been fully illustrated. In an earlier published study we have demonstrated that exposure of the VSMC line, PAC-1, to Transforming growth factor-beta 1 (TGF-beta 1), activated PKN (a RhoA-dependent kinase). Here we show that exposure to TGF-beta 1 delays the G(2)/M transition by 2 hrs in G(1)/S synchronized and released PAC-1 culture. This delay is abolished by the RhoA kinase inhibitors, HA1077 or Y-27632. More importantly, RNAi knockdown of PKN expression prevents the G(2)/M transition delay induced by TGF-beta 1. Changes in PKN activity temporally correlates to the G(2)/M transition timing. Moreover, Cdc25C is phosphorylated by the TGF-beta 1-activated PKN. PKN and Cdc25C coimmunoprecipitate with each other. Finally, PKN and Cdc25C colocalize to the nuclear region only during the critical period of time prior to entry into the M phase. Our data demonstrate that Cdc25C activity is negatively regulated by TGF-beta 1-stimulated PKN. Once activated through TGF-beta 1 signaling, PKN binds to and phosphorylates Cdc25C. The physical interaction and phosphorylation result in an inactivation of Cdc25C and delay the VSMC entry into the M stage of the cell cycle.
引用
收藏
页码:739 / 749
页数:11
相关论文
共 72 条
  • [1] The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity
    Amano, M
    Chihara, K
    Nakamura, N
    Kaneko, T
    Matsuura, Y
    Kaibuchi, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) : 32418 - 32424
  • [2] The specificities of protein kinase inhibitors: an update
    Bain, J
    McLauchlan, H
    Elliott, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2003, 371 : 199 - 204
  • [3] Cell cycle progression - New therapeutic target for vascular proliferative disease
    Braun-Dullaeus, RC
    Mann, MJ
    Dzau, VJ
    [J]. CIRCULATION, 1998, 98 (01) : 82 - 89
  • [4] CYCLIN-LIKE ACCUMULATION AND LOSS OF THE PUTATIVE KINETOCHORE MOTOR CENP-E RESULTS FROM COUPLING CONTINUOUS SYNTHESIS WITH SPECIFIC DEGRADATION AT THE END OF MITOSIS
    BROWN, KD
    COULSON, RMR
    YEN, TJ
    CLEVELAND, DW
    [J]. JOURNAL OF CELL BIOLOGY, 1994, 125 (06) : 1303 - 1312
  • [5] Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion
    Calautti, E
    Grossi, M
    Mammucari, C
    Aoyama, Y
    Pirro, M
    Ono, Y
    Li, J
    Dotto, GP
    [J]. JOURNAL OF CELL BIOLOGY, 2002, 156 (01) : 137 - 148
  • [6] Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
    Chaturvedi, P
    Eng, WK
    Zhu, Y
    Mattern, MR
    Mishra, R
    Hurle, MR
    Zhang, XL
    Annan, RS
    Lu, Q
    Faucette, LF
    Scott, GF
    Li, XT
    Carr, SA
    Johnson, RK
    Winkler, JD
    Zhou, BBS
    [J]. ONCOGENE, 1999, 18 (28) : 4047 - 4054
  • [7] CDC2 REGULATORY FACTORS
    COLEMAN, TR
    DUNPHY, WG
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1994, 6 (06) : 877 - 882
  • [8] Dalal SN, 1999, MOL CELL BIOL, V19, P4465
  • [9] Damdinsuren B, 2006, ONCOL REP, V15, P401
  • [10] Specificity and mechanism of action of some commonly used protein kinase inhibitors
    Davies, SP
    Reddy, H
    Caivano, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2000, 351 (351) : 95 - 105